FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220902153> ?p ?o ?g. }

• W4220902153 endingPage "393" @default.
• W4220902153 startingPage "385" @default.
• W4220902153 abstract "Polycystic ovarian syndrome (PCOS) is a frequent metabolic disorder in premenopausal woman, featured with increased androgen, reduced ovulation and insulin resistance. An increasing number of reports have confirmed that microRNAs (miRNAs) play pivotal roles in PCOS. However, the diagnostic mechanisms of microRNA (miR)-206 in PCOS remain unclear. Liquiritin, extracted from Glycyrrhiza Radix, has multiple pharmacological activities in diseases, including PCOS. Our report was designed to explore whether liquiritin play a role in PCOS by regulating human ovarian granulosa cell-like KGN cells proliferation and apoptosis through miR-206/phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) pathway, and to further elucidate the underlying molecular mechanisms. KGN cells were exposed to various concentration (0, 20, 40, 80 μM) of liquiritin for 48 h, cell proliferation and apoptosis were measured by 3-(45)-dimethylthiahiazo(-z-y1)-35-di-phenytetrazoliumromide (MTT) and flow cytometry analysis. Reverse transcription‑quantitative polymerase chain reaction was conducted to checked the levels of miR-206 in KGN cells. The protein expression levels of cleaved caspase3, caspase3, phosphorylated (p)-AKT and AKT were analyzed using Western blot assay. We found that liquiritin stimulation led to reduced viability and enhanced apoptotic KGN cells, which along with increased cleaved caspase3 and cleaved caspase3/caspase3 ratio. Moreover, liquiritin obviously reduced p-AKT expression and p-AKT/AKT ratio. MiR-206 was up-regulated in liquiritin-treated KGN cells, however, all these results were reversed by miR-206 inhibitor. In conclusion, our findings suggested that liquiritin exerted anti-proliferative and apoptosis-inducing roles in KGN cells via miR-206/PI3K/AKT pathway, suggesting that liquiritin may be an effective therapeutic target for PCOS treatment." @default.
• W4220902153 created "2022-04-03" @default.
• W4220902153 creator A5003115005 @default.
• W4220902153 creator A5060619318 @default.
• W4220902153 creator A5071740423 @default.
• W4220902153 date "2022-03-21" @default.
• W4220902153 modified "2023-10-06" @default.
• W4220902153 title "Protective effects of liquiritin on polycystic ovary syndrome through modulating ovarian granulosa cell proliferation and apoptosis via miR-206/PI3K/AKT pathway" @default.
• W4220902153 cites W2107277218 @default.
• W4220902153 cites W2157755159 @default.
• W4220902153 cites W2192080449 @default.
• W4220902153 cites W2281144979 @default.
• W4220902153 cites W2521532521 @default.
• W4220902153 cites W2550927336 @default.
• W4220902153 cites W2735933898 @default.
• W4220902153 cites W2751562657 @default.
• W4220902153 cites W2757062831 @default.
• W4220902153 cites W2806655023 @default.
• W4220902153 cites W2894385852 @default.
• W4220902153 cites W2915931316 @default.
• W4220902153 cites W2955848158 @default.
• W4220902153 cites W2972466651 @default.
• W4220902153 cites W2978735602 @default.
• W4220902153 cites W2980245763 @default.
• W4220902153 cites W2987017313 @default.
• W4220902153 cites W2990062554 @default.
• W4220902153 cites W2990562098 @default.
• W4220902153 cites W2994946132 @default.
• W4220902153 cites W2999009404 @default.
• W4220902153 cites W3000476603 @default.
• W4220902153 cites W3003554736 @default.
• W4220902153 cites W3019164864 @default.
• W4220902153 cites W3021966723 @default.
• W4220902153 cites W3023804528 @default.
• W4220902153 cites W3024243615 @default.
• W4220902153 cites W3027481866 @default.
• W4220902153 cites W3085059470 @default.
• W4220902153 cites W3091916369 @default.
• W4220902153 cites W3095202855 @default.
• W4220902153 cites W3107923937 @default.
• W4220902153 cites W3118450155 @default.
• W4220902153 cites W3131448175 @default.
• W4220902153 cites W3169738633 @default.
• W4220902153 doi "https://doi.org/10.1007/s10616-022-00531-5" @default.
• W4220902153 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35733703" @default.
• W4220902153 hasPublicationYear "2022" @default.
• W4220902153 type Work @default.
• W4220902153 citedByCount "3" @default.
• W4220902153 countsByYear W42209021532022 @default.
• W4220902153 countsByYear W42209021532023 @default.
• W4220902153 crossrefType "journal-article" @default.
• W4220902153 hasAuthorship W4220902153A5003115005 @default.
• W4220902153 hasAuthorship W4220902153A5060619318 @default.
• W4220902153 hasAuthorship W4220902153A5071740423 @default.
• W4220902153 hasBestOaLocation W42209021532 @default.
• W4220902153 hasConcept C104317684 @default.
• W4220902153 hasConcept C126322002 @default.
• W4220902153 hasConcept C134018914 @default.
• W4220902153 hasConcept C179998833 @default.
• W4220902153 hasConcept C185592680 @default.
• W4220902153 hasConcept C190283241 @default.
• W4220902153 hasConcept C2776415932 @default.
• W4220902153 hasConcept C2777391703 @default.
• W4220902153 hasConcept C2779306644 @default.
• W4220902153 hasConcept C2780536827 @default.
• W4220902153 hasConcept C3018442814 @default.
• W4220902153 hasConcept C43617362 @default.
• W4220902153 hasConcept C55493867 @default.
• W4220902153 hasConcept C71924100 @default.
• W4220902153 hasConcept C75217442 @default.
• W4220902153 hasConcept C86554907 @default.
• W4220902153 hasConcept C86803240 @default.
• W4220902153 hasConcept C95444343 @default.
• W4220902153 hasConceptScore W4220902153C104317684 @default.
• W4220902153 hasConceptScore W4220902153C126322002 @default.
• W4220902153 hasConceptScore W4220902153C134018914 @default.
• W4220902153 hasConceptScore W4220902153C179998833 @default.
• W4220902153 hasConceptScore W4220902153C185592680 @default.
• W4220902153 hasConceptScore W4220902153C190283241 @default.
• W4220902153 hasConceptScore W4220902153C2776415932 @default.
• W4220902153 hasConceptScore W4220902153C2777391703 @default.
• W4220902153 hasConceptScore W4220902153C2779306644 @default.
• W4220902153 hasConceptScore W4220902153C2780536827 @default.
• W4220902153 hasConceptScore W4220902153C3018442814 @default.
• W4220902153 hasConceptScore W4220902153C43617362 @default.
• W4220902153 hasConceptScore W4220902153C55493867 @default.
• W4220902153 hasConceptScore W4220902153C71924100 @default.
• W4220902153 hasConceptScore W4220902153C75217442 @default.
• W4220902153 hasConceptScore W4220902153C86554907 @default.
• W4220902153 hasConceptScore W4220902153C86803240 @default.
• W4220902153 hasConceptScore W4220902153C95444343 @default.
• W4220902153 hasIssue "3" @default.
• W4220902153 hasLocation W42209021531 @default.
• W4220902153 hasLocation W42209021532 @default.
• W4220902153 hasLocation W42209021533 @default.
• W4220902153 hasOpenAccess W4220902153 @default.
• W4220902153 hasPrimaryLocation W42209021531 @default.
• W4220902153 hasRelatedWork W2024933597 @default.

• next